Asunto(s)
Endarterectomía/métodos , Predicción , Hipertensión Pulmonar/cirugía , Trasplante de Pulmón , Arteria Pulmonar/cirugía , Embolia Pulmonar/complicaciones , Enfermedad Crónica , Estudios de Seguimiento , Humanos , Hipertensión Pulmonar/diagnóstico , Hipertensión Pulmonar/etiología , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/cirugía , Estudios RetrospectivosRESUMEN
PURPOSE: The study investigates Quality of Life (QOL) and correlation with functional status of patients affected by Chronic Thromboembolic Pulmonary Hypertension who undergo Pulmonary Endoarterectomy. METHODS: We investigated with an observational design (before surgery, three and twelve months afterwards) the hemodynamic data (NYHA class, mean pulmonary arterial pressure, cardiac output and pulmonary vascular resistance), the functional status (using the 6-Minute Walk Test) and the QOL, using three questionnaires: Medical Outcome Study Short Form-36 (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Saint George Respiratory Questionnaire (SGRQ). We report the results of forty-nine patients. RESULTS: After surgery there was an improvement on functional and hemodynamic parameters and on QOL. The physical domain (PCS) of SF-36 was weakly but significantly associated with all functional parameters. There was no association between functional parameters and mental domain (MCS) of SF-36 or SGRQ. The improvement in 6-Minute Walk Distance was associated with an increase in MLHFQ. CONCLUSIONS: Both QOL and submaximal exercise tolerance improve after surgery. However only the physical domains of SF-36 appear to be significantly associated to the functional data.
Asunto(s)
Endarterectomía , Hipertensión Pulmonar/fisiopatología , Hipertensión Pulmonar/cirugía , Embolia Pulmonar/fisiopatología , Embolia Pulmonar/cirugía , Calidad de Vida , Prueba de Esfuerzo , Femenino , Hemodinámica , Humanos , Hipertensión Pulmonar/etiología , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Embolia Pulmonar/complicaciones , Encuestas y CuestionariosRESUMEN
We report a successful follow-up after 28 years of a woman with obliterative restrictive endomyocardial fibrosis (EMF) that underwent complete surgical decortication with simultaneous mitral and tricuspid bioprosthetic valve replacement in 1982 and underwent successful reoperation for the structural failure of biological prostheses after 25 years.
Asunto(s)
Bioprótesis , Fibrosis Endomiocárdica/diagnóstico , Fibrosis Endomiocárdica/cirugía , Implantación de Prótesis de Válvulas Cardíacas/métodos , Insuficiencia de la Válvula Mitral/cirugía , Válvula Mitral/cirugía , Falla de Prótesis/efectos adversos , Insuficiencia de la Válvula Tricúspide/cirugía , Válvula Tricúspide/cirugía , Adulto , Ecocardiografía Transesofágica , Femenino , Estudios de Seguimiento , Humanos , Insuficiencia de la Válvula Mitral/diagnóstico , Reoperación , Factores de Tiempo , Resultado del Tratamiento , Insuficiencia de la Válvula Tricúspide/diagnósticoRESUMEN
BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplant (LTX) is still being debated. METHODS: We performed a retrospective two-center analysis of the relationship between ECMO bridging duration and survival in 25 patients. Further survival analysis was obtained by dividing the patients according to waiting time on ECMO: up to 14 days (Early group) or longer (Late group). We also analyzed the impact of the ventilation strategy during ECMO bridging (ie, spontaneous breathing and noninvasive ventilation [NIV] or intubation and invasive mechanical ventilation [IMV]). RESULTS: Seventeen of 25 patients underwent a transplant (with a 76% 1-year survival), whereas eight patients died during bridging. In the 17 patients who underwent a transplant, mortality was positively related to waiting days until LTX (hazard ratio [HR], 1.12 per day; 95% CI, 1.02-1.23; P = .02), and the Early group showed better Kaplan-Meier curves (P = .02), higher 1-year survival rates (100% vs 50%, P = .03), and lower morbidity (days on IMV and length of stay in ICU and hospital). During the bridge to transplant, mortality increased steadily with time. Considering the overall outcome of the bridging program (25 patients), bridge duration adversely affected survival (HR, 1.06 per day; 95% CI, 1.01-1.11; P = .015) and 1-year survival (Early, 82% vs Late, 29%; P = .015). Morbidity indexes were lower in patients treated with NIV during the bridge. CONCLUSIONS: The duration of the ECMO bridge is a relevant cofactor in the mortality and morbidity of critically ill patients awaiting organ allocation. The NIV strategy was associated with a less complicated clinical course after LTX.
Asunto(s)
Enfermedad Crítica/mortalidad , Oxigenación por Membrana Extracorpórea/métodos , Unidades de Cuidados Intensivos , Trasplante de Pulmón/métodos , Listas de Espera , Adulto , Enfermedad Crítica/terapia , Femenino , Humanos , Italia/epidemiología , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Respiración Artificial , Estudios Retrospectivos , Tasa de Supervivencia/tendencias , Resultado del Tratamiento , Adulto JovenRESUMEN
The aim of this study was to evaluate the safety and performance of the Arrow CorAide left ventricular assist system (LVAS) (Arrow International, Reading, PA, USA), a continuous-flow left ventricular assist device, as bridge to transplantation or recovery as well as destination therapy in patients with New York Heart Association (NYHA) class IV heart failure. Twenty-one patients were implanted with the CorAide LVAS between February 2005 and February 2006 in a prospective, multicenter, nonrandomized trial. Seventeen patients (81%) survived to >180 days or to transplantation. The cumulative time on device was 16.58 patient years (range 23-796 days, median 192 days). No intraoperative technical issues were observed at the time of implantation. Of the 21 implants, nine patients died on device, two were converted to other devices, and 10 were transplanted. Three patient deaths were attributed to pump polymer coating delamination. Postmortem device inspection determined delamination of the polymer coating on the pump's internal surface to be the cause of the late hemolysis and sudden fatal pump stops. No embolic or driveline infection event was recorded. The automatic flow control algorithm functioned reliably throughout the trial. Primary performance trial endpoint was achieved with 81% survival to 180 days or transplantation. Delamination of the polymer coating on the internal surface of the pump with resultant hemolysis and pump stops was the sole major device event in this trial. Elimination of the polymer coating and replacement with an amorphous carbon coating has resolved this in preclinical testing, prior to initiation of further clinical testing of this device.
Asunto(s)
Materiales Biocompatibles Revestidos , Insuficiencia Cardíaca/terapia , Corazón Auxiliar , Polímeros , Función Ventricular Izquierda , Anciano , Europa (Continente) , Femenino , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/mortalidad , Insuficiencia Cardíaca/fisiopatología , Trasplante de Corazón , Corazón Auxiliar/efectos adversos , Hemólisis , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Diseño de Prótesis , Falla de Prótesis , Factores de Tiempo , Resultado del TratamientoRESUMEN
The development of new immunosuppressive drugs for kidney transplantation resulted both in better short-term outcomes and in decreased metabolic, cardiovascular, and nephrotoxicity risk. Belatacept belongs to a new class of immunosuppressive drugs that selectively inhibits T-cell activation by preventing CD28 activation and by binding its ligands B7-1 and B7-2. The result is an inactivation of costimulatory pathways. A comparative analysis of the BENEFIT and BENEFIT-EXT datasets showed belatacept regimens resulted in better cardiovascular and metabolic risk profiles than did cyclosporin A (CsA) regimens: belatacept likewise outperformed CsA in terms of lower blood pressure and serum lipids and less new onset diabetes after transplantation. About 20% of belatacept-treated patients developed adverse effects which included anemia, pyrexia, neutropenia, diarrhea, urinary tract infection, headache, and peripheral edema. At present, belatacept does not seem to predispose patients to a higher rate of infection than CsA maintenance immunosuppression. The risk of posttransplant lymphoproliferative diseases was higher in Epstein-Barr virus (EBV)-seronegative patients than in EBV-seropositive patients, but the risk may be reduced by use of a less intensive regimen and avoidance of EBV-negative patients and of patients whose pretransplant EBV serology is unknown. Belatacept provides a new option for immunosuppressive therapy in kidney transplantation, but needs further evaluation in terms of the late effects that may derive from prolonged blockage of the costimulatory system and the induction of tolerance status.
Asunto(s)
Aneurisma Coronario/cirugía , Trombosis Coronaria/cirugía , Infarto del Miocardio/etiología , Síndrome Coronario Agudo/etiología , Adulto , Procedimientos Quirúrgicos Cardíacos , Aneurisma Coronario/complicaciones , Angiografía Coronaria , Trombosis Coronaria/complicaciones , Femenino , Humanos , Resultado del TratamientoRESUMEN
BACKGROUND AND AIM OF THE STUDY: Aortic valve-sparing (AVS) procedures have been introduced to treat ascending aorta dilatation and aortic valve insufficiency in the presence of preserved native aortic valve leaflets. Although the surgical technique has been standardized, the choice of best type and size of Dacron graft to be used remains a matter of debate. Herein are presented preliminary results based on a patient-specific finite element model aimed at optimizing the Dacron prosthesis size and shape. Previously, finite element analysis (FEA) has been applied to investigate medical problems and, in particular, to better evaluate the pathophysiology of the aortic root. To date, however, such methodology has not been applied to the patient-specific evaluation of AVS postoperative results. METHODS: The framework of the FEA study included four steps: (i) the creation of a mathematic model of the patient's aortic root; (ii) the creation of a model for two different Dacron grafts (the standard straight graft and a Valsalva graft), with sizes of each type ranging from 24 to 30 mm; (iii) a virtual computer-based simulation of the AVS procedure, using each graft; and (iv) a virtual computer-based simulation of the diastolic closure of the repaired valve and an evaluation of post-implant physiology, based on three parameters: the height of coaptation ratio (H(C)R); the length of coaptation ratio (L(C)R); and the distance between the central point of coaptation and the ideal geometrical centre (D(C)). RESULTS: The simulation results of post-implant performance of the aortic valve revealed that both H(C)R and L(C)R were decreased as the graft size was increased, but no significant differences were identified between two types of graft. In contrast, the Valsalva graft, when compared to the standard straight graft, led to a significant reduction in D(C). The results in terms of H(C)R, L(C)R and D(C) recommended unequivocally, for the specific case under investigation, that a 30 mm straight graft and a 28 mm Valsalva graft would ensure the most physiological valve behavior for the patient under investigation. CONCLUSION: In evaluating the potential of a preoperative prediction of the optimal graft size, using FEA, the virtual simulation of the AVS procedure proved to be feasible and useful in predicting the postoperative physiology of the aortic root. In particular, this finite element model might have a clinical impact as may be used to optimize the surgeon's choice of prosthesis size.
Asunto(s)
Enfermedades de la Aorta/cirugía , Insuficiencia de la Válvula Aórtica/cirugía , Válvula Aórtica , Prótesis Valvulares Cardíacas , Modelos Cardiovasculares , Análisis de Elementos Finitos , HumanosRESUMEN
BACKGROUND: The present study was aimed at determining the impact of type 2 diabetes mellitus (DM) on postoperative bioprosthetic structural valve degeneration. METHODS AND RESULTS: Twelve Italian centers participated in the study. Patient data refer to bioprosthetic implantations performed from November 1988 to December 2009, which resulted in 6184 patients (mean age 71.3±5.4 years, 60.1% male) being enrolled. Of these patients, 1731 (27.9%) had type 2 DM. The propensity score-matching algorithm successfully matched 1113 patients with type 2 DM with the same number of no-DM patients. The postmatching standard differences were less than 0.1 for each of the covariates, and 64.2% of DM patients were matched. The early (30 days) mortality rate was 7.8% (n=87) versus 2.9% (n=33) in patients with or without type 2 DM (P<0.001), respectively. Seven-year freedom from valve deterioration was significantly lower in patients with DM (73.2% [95% confidence interval, 61.6-85.5] versus 95.4% [95% confidence interval, 83.9-100], P<0.001). In Cox regression models with robust SEs that accounted for the clustering of matched pairs, DM was the strongest predictor of structural valve degeneration (hazard ratio 2.39 [95% confidence interval 2.28-3.52]). When we allowed for interaction between type 2 DM and other key risk factors, DM remained a significant predictor beyond any potentially associated variable. CONCLUSIONS: Patients with type 2 DM undergoing bioprosthetic valve implantation are at high risk of early and long-term mortality, as well as of structural valve degeneration.
Asunto(s)
Bioprótesis/estadística & datos numéricos , Diabetes Mellitus Tipo 2/mortalidad , Enfermedades de las Válvulas Cardíacas/mortalidad , Prótesis Valvulares Cardíacas/estadística & datos numéricos , Complicaciones Posoperatorias/mortalidad , Falla de Prótesis/efectos adversos , Anciano , Femenino , Estudios de Seguimiento , Hemoglobina Glucada/metabolismo , Enfermedades de las Válvulas Cardíacas/cirugía , Humanos , Hiperglucemia/mortalidad , Incidencia , Unidades de Cuidados Intensivos/estadística & datos numéricos , Italia/epidemiología , Masculino , Análisis Multivariante , Valor Predictivo de las Pruebas , Factores de RiesgoRESUMEN
Minimally invasive video-assisted surgery through a right minithoracotomy has become the standard surgical approach for several cardiac diseases at many major centers worldwide. In this article we review the existing literature on the subject and describe different operative techniques, application fields and clinical outcomes.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos/métodos , Cardiopatías/cirugía , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Cirugía Asistida por Video/métodos , HumanosRESUMEN
PURPOSE: In the case of an acute aortic dissection, a surgical aortic procedure is usually the priority in order to restore the perfusion of vital organs. Afterwards, associated ischemic abdominal visceral lesions can be resected. For particular patients, it could be highly beneficial to perform the abdominal surgery before surgically addressing the aorta. The aim of this paper is to contribute to the therapeutic choice in cases of acute aortic dissection with acute abdomen. CASE REPORT: The case is reported of a 38-year-old patient, affected by an acute aortic dissection (Stanford type A) and peritonitis.Suspecting the necessity for a complex combined surgical procedure, the patient underwent emergency diagnostic laparoscopy, which showed an infarctual necrosis of the distal ileum and right colon. Therefore, he immediately underwent a wide right hemicolectomy. Afterwards, an ascending aortic substitution was performed.The patient was discharged on the 15th post-operative day, and he is doing well, 1 year and 3 months after the operation. CONCLUSION: In the case of an acute aortic dissection with acute abdomen, emergency laparoscopy is a precious surgical technique to identify criteria that can lead to therapeutic decisions, including timing.
Asunto(s)
Aneurisma de la Aorta/cirugía , Disección Aórtica/cirugía , Implantación de Prótesis Vascular , Colectomía , Intestinos/irrigación sanguínea , Isquemia/cirugía , Abdomen Agudo/etiología , Enfermedad Aguda , Adulto , Disección Aórtica/complicaciones , Disección Aórtica/diagnóstico por imagen , Aneurisma de la Aorta/complicaciones , Aneurisma de la Aorta/diagnóstico por imagen , Aortografía/métodos , Humanos , Isquemia/diagnóstico , Isquemia/etiología , Laparoscopía , Masculino , Necrosis , Peritonitis/etiología , Factores de Tiempo , Tomografía Computarizada por Rayos X , Resultado del TratamientoAsunto(s)
Angioplastia Coronaria con Balón/métodos , Enfermedad de la Arteria Coronaria/cirugía , Vasos Coronarios/cirugía , Vena Safena/fisiología , Grado de Desobstrucción Vascular , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Enfermedad de la Arteria Coronaria/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Vena Safena/trasplante , Factores de Tiempo , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Elevated heart rate (HR) has been indicated as risk factor for cardiovascular disease. Experimental data support a role of HR in the progression and severity of atherosclerotic lesions. Sinus tachycardia is common in heart transplant patients due to the lack of autonomic control. This study assessed the role of HR in the development of cardiac allograft vasculopathy (CAV) in heart transplant recipients. METHODS: Data from 244 allograft recipients were analyzed. Known factors affecting CAV and mean HR obtained from 24-hour recordings at 1 year (dichotomized at ≥90 beats/min) were tested in univariate and multivariable Cox analysis. RESULTS: During a median of 96 months, 60 patients (25%) experienced CAV. Surprisingly, HR < 90 but not ≥90 beats/min was significantly associated with an increased CAV development. Univariate analysis showed several predictors were associated with the end point; however, at multivariable analysis, only donor's age, chronic renal failure, and left ventricular end-diastolic wall thickness were significant predictors of CAV, with hazard ratios of 1.02 (95% confidence interval, 1.00-1.04), 1.90 (1.13-3.21), and 1.11 (1.00-1.22), respectively. A highly statistically significant difference in donor's age was found among patients with mean heart rate ≥90 or <90 beats/min (30 ± 13 vs 40 ± 14 years, p < 0.0001). CONCLUSIONS: In the denervated heart, sinus tachycardia is not a risk factor for coronary atherosclerosis. HR in heart transplant recipients reflects "intrinsic heart rate" and is a simple epiphenomenon of the donor's age.
Asunto(s)
Enfermedad de la Arteria Coronaria/epidemiología , Frecuencia Cardíaca/fisiología , Trasplante de Corazón/fisiología , Taquicardia Ventricular/complicaciones , Enfermedades Vasculares/epidemiología , Adulto , Factores de Edad , Electroencefalografía , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Factores de Riesgo , Taquicardia Ventricular/fisiopatología , Trasplante HomólogoRESUMEN
We present postoperative and midterm (3 years) angiographic changes after removal of five (of six) occluded stents from the left anterior descending (LAD) coronary artery and its reconstruction with a 9-cm-long on-lay patching done with the left internal mammary artery.
Asunto(s)
Reestenosis Coronaria/cirugía , Anastomosis Interna Mamario-Coronaria/métodos , Stents , Angiografía Coronaria , Reestenosis Coronaria/diagnóstico por imagen , Reestenosis Coronaria/etiología , Remoción de Dispositivos , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Ionescu-Shiley valve was withdrawn from clinical use in 1987 for its early structural failure after implantation. This was due to valve design rather than the natural properties of bovine pericardium itself. We describe the unexpected 25-year survival of an Ionescu-Shiley bioprosthesis in the mitral and tricuspid positions, implanted to treat endomyocardial fibrosis. This report makes 2 important points: (1) pannus overgrowth may be a favorable determinant of the durability of xenografts, and (2) bovine pericardial valves may have excellent hemodynamic performance and tissue durability for more than 20 years in the mitral position even in young patients.